Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients

HIV Clinical Trials

Volumn 17, Issue 3, 2016, Pages 109-113

  Sayan, M ^a,b   Gunduz A ^c   Ersoz G ^d   Inan A ^c   Deveci, A ^e   Ozgur G ^f   Sargin F ^g   Karagoz G ^h   Inci A ^c   Inan D ⁱ   Ulcay A ^j   Karaoglan I ^k   Kaya, S ^l   Kutlu, S S ^m   Suer K ^b   Cagatay A ⁿ   Akalin H ^o  

^a KOCAELI UNIVERSITY   (Turkey)

^b NEAR EAST UNIVERSITY   (Turkey)

^c Education and Research Hospital   (Turkey)

^d MERSIN UNIVERSITY   (Turkey)

^e ONDOKUZ MAYIS UNIVERSITY   (Turkey)

^f Samsun Education and Research Hospital   (Turkey)

^g GOZTEPE TRAINING AND RESEARCH HOSPITAL   (Turkey)

^h Umraniye Education and Research Hospital   (Turkey)

ⁱ AKDENIZ UNIVERSITY   (Turkey)

^j GULHANE SCHOOL OF MEDICINE   (Turkey)

^k GAZIANTEP UNIVERSITY   (Turkey)

^l KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^m PAMUKKALE UNIVERSITY   (Turkey)

ⁿ ISTANBUL UNIVERSITY   (Turkey)

^o ULUDAG UNIVERSITY   (Turkey)

more..

Author keywords

DNA sequencing; Dolutegravir; Drug resistance; Elvitegravir; HIV 1 integrase; Integrase inhibitors; Raltegravir

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ELVITEGRAVIR; INTEGRASE; INTEGRASE STRAND TRANSFER INHIBITOR; PROTEINASE; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG; VIRUS RNA; CODON; INTEGRASE INHIBITOR;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CYTOMEGALOVIRUS INFECTION; DELTA AGENT HEPATITIS; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; PSEUDOMONAS PNEUMONIA; STRUCTURAL GENE; THRUSH; TOXOPLASMOSIS; TURKISH CITIZEN; VIRUS DETECTION; VIRUS MUTATION; AGED; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; CODON; DRUG EFFECTS; GENETICS; GENOTYPE; HIV INFECTIONS; MICROBIAL SENSITIVITY TEST; MIDDLE AGED; MUTATION; RISK FACTOR; TRANSMISSION; TURKEY; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADULT; AGED; AMINO ACID SUBSTITUTION; CD4 LYMPHOCYTE COUNT; CODON; COINFECTION; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; RISK FACTORS; RNA, VIRAL; TURKEY; VIRAL LOAD; YOUNG ADULT;

EID: 84978630564     PISSN: 15284336     EISSN: 19455771     Source Type: Journal    
DOI: 10.1080/15284336.2016.1153303     Document Type: Article

References (24)

1. J.L.Mbisa, S.A.Martin, P.A.Cane. Patterns of resistance development with integrase inhibitors in HIV. Infect Drug Resist. 2011;4:65–76.
2. S.Y.Rhee, T.F.Liu, M.Kiuchi, R.Zioni, R.J.Gifford, S.P.Holmes,. Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology. 2008;5:74. doi:10.1186/1742-4690-5-74.
3. R.Kulkarni, M.E.Abram, D.J.McColl, T.Barnes, M.W.Fordyce, J.Szwarcberg,. Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir df versus atazanavir+ritonavir+emtricitabine/tenofovir df in antiretroviral-naïve patients. HIV Clin Trials. 2014;15:218–230.10.1310/hct1504-218
4. A.Fantauzzi, I.Mezzaroma. Dolutegravir: Clinical efficacy and role in HIV therapy. Ther Adv Chronic Dis. 2014;5:164–177.10.1177/2040622314530461
5. A.M.Vandamme, R.J.Camacho, F.C.Silberstein, A.de Luca, L.Palmisano, D.Paraskevis,. European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev. 2011;13:77–108.
6. European AIDS Clinical Society (EACS) Guidelines. (2013): Version 7.0, October 2013. www.europeanaidsclinicalsociety.org.
7. British HIV Association guidelines for the treatment of. HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013). HIV Medicine. 2014;15(Suppl. 1):1–85.
8. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 13 November, 2014. Available at: http://www.aidsinfo.nih.gov.
9. D.E.Bennett, R.J.Camacho, D.Otelea, D.R.Kuritzkes, H.Fleury, M.Kiuchi,. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 Update. PLoS ONE. 2009;4:e4724.10.1371/journal.pone.0004724
10. P.Sax, R.Islam, R.Walensky, E.Losina, M.C.Weinstein, S.J.Goldie,. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005;41:1316–1323.
11. Hacettepe University, HIV/AIDS Treatment and Research Centre. The 2014 Annual Report. http://www.hatam.hacettepe.edu.tr.
12. M.Sayan, A.Willke, N.Ozgunes, F.Sargin. HIV-1 subtypes and primary antiretroviral resistance mutations in antiretroviral therapy Naive HIV-1 ınfected ındividuals in Turkey. Jpn J Infect Dis. 2013;66:306–311.10.7883/yoken.66.306
13. M.Sayan, F.Sargin, D.Inan, D.S.Yildiz, A.K.Celikbas, K.Yasar,. HIV-1 transmitted drug resistance mutations in newly diagnosed antiretroviral-naive patients in Turkey. AIDS Res Hum Retro. 2016;32:26–31.10.1089/aid.2015.0110
14. Centers for Disease Control and Prevention. Guidelines for national human immunodeficiency virus case surveillance, including monitoring for human immunodeficiency virus infection and acquired immunodeficiency syndrome. MMWR Recomm Rep Dec 1999;10(48):1–27.
15. M.Casadellà, P.M.van Ham, M.Noguera-Julian, A.van Kessel, C.Pou, L.M.Hofstra, J.R.Santos,. Primary resistance to integrase strand-transfer inhibitors in Europe. J Antimicrob Chemother. 2015;70:2885–2888.10.1093/jac/dkv202
16. M.Karolin, P.Y.Kaveh, S.Sybille, F.Stefan, B.Barbara, K.Max von, Characterization of natural polymorphic sites of the HIV-1 integrase before the introduction of HIV-1 integrase inhibitors in Germany. J Int AIDS Soc 2014;17(Supl 3):19746.
17. C.Gutierrez, B.H.Novoa, M.J.P.Elias, A.M.Moreno, A.Holguin, F.Dronda,. Prevalence of primary resistance mutations to ıntegrase ınhibitors in treatment-naïve and -experienced patients ınfected with B and non-B HIV-1 variants. HIV Clin Trials. 2013;14:10–16.10.1310/hct1401-10
18. S.Dimonte, M.B.Mina, S.Aquaro, C.F.Perno. Natural polymorphisms of HIV-1 subtype-C integrase coding region in a large group of ARV-naïve infected individuals. Infection. 2013;41:1097–1102.10.1007/s15010-013-0464-5
19. S.H.Eshleman, S.E.Hudelson, P.Smith, H.J.JHackett Jr, V.Holzmayer, P.Swanson,. Analysis of pol ıntegrase sequences in diverse HIV type 1 strains using a prototype genotyping assay. AIDS Res Hum Retro. 2009;25:343–345.10.1089/aid.2008.0236
20. C.B.Passaes, M.L.Guimarães, S.L.Fernandez, R.S.Lorete, S.L.Teixeira, J.C.Fernandez,. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. J Acquir Immune Defic Syndr. 2009;51:7–12.
21. M.Q.Fish, R.Hewer, C.L.Wallis, W.D.Venter, W.S.Stevens, M.A.Papathanasopoulos. Natural polymorphisms of integrase among HIV type 1-ınfected South African patients. AIDS Res Hum Retro. 2010;26:489–493.10.1089/aid.2009.0249
22. D.Inan, M.Sayan. Molecular epidemiology of HIV-1 strains in Antalya, Turkey. J Int AIDS Soc 2014;17(4 Suppl 3):19684.
23. UNHCR official web page. http://www.unhcr.org/pages/49e48e0fa7 f.html
24. Trafficking in human beings report of European Commission. https://ec.europa.eu/anti-trafficking